[Tienilic acid in the treatment of arterial hypertension and congestive cardiac insufficiency]. 1979

R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan

Tienilic acid (TA) is a common new diuretic agent with a potent uricosuric action. In a double-blind cross-over study its antihypertensive effect was compared to that of hydrochlorothiazide (HCT). 20 patients with essential hypertension were studied: after I weeks of placebo wash-out 10 patients received TA (dose range 250-750 mg/die) and 10 HCT (dose range 50-150 mg/die), for 5 weeks. Systolic and diastolic blood pressures were significantly and equally reduced (p < 0.001) after the first week of treatment in both groups. While serum uric acid concentration increased after HCT, it was significantly reduced (p < 0.001) after TA treatment. Serum potassium was slightly reduced with both treatments. Serum tryglicerides, unchanged after HCT, showed a slight tendency to reduction on TA treatment. Ten patients with congestive heart failure, on full digitalis treatment, were given TA (dose range 250-1000 mg/die): in each patient a prompt diuretic effect was observed, associated to a significant reduction of body weight and to a marked improvement of the clinical signs of heart failure. Therefore, TA is an effective diuretic agent which may be conveniently used in the treatment of arterial hypertension and congestive heart failure, as it induces a diuretic effect comparable to that obtained with HCT, reducing at the same time, serum uric acid levels.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D004231 Diuresis An increase in the excretion of URINE. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Diureses
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006016 Glycolates Derivatives of ACETIC ACID which contain an hydroxy group attached to the methyl carbon. 2-Hydroxyacetates,Glycolate Ethers,Hydroxyacetate Ethers,Hydroxyacetates,Hydroxyacetic Acids,2 Hydroxyacetates,Acids, Hydroxyacetic,Ethers, Glycolate,Ethers, Hydroxyacetate
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure

Related Publications

R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
January 1981, Minerva nefrologica,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
January 1980, Advances in experimental medicine and biology,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
May 1978, Canadian Medical Association journal,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
May 1963, Medicina interna,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
January 1951, Revista brasileira de medicina,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
November 1958, Medicina,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
January 1980, Clinical and experimental pharmacology & physiology,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
May 1982, La Clinica terapeutica,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
August 1980, Annals of the rheumatic diseases,
R Fariello, and E Agabiti-Rosei, and C Alicandri, and L Corea, and T Oldoni, and G Muiesan
January 1977, Bulletin de la Societe medicale d'Afrique noire de langue francaise,
Copied contents to your clipboard!